Cancer Research Meeting Calendar  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gri, G.
Right arrow Articles by Colombo, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gri, G.
Right arrow Articles by Colombo, M. P.
[Cancer Research 62, 4390-4397, August 1, 2002]
© 2002 American Association for Cancer Research


Immunology

Antitumor Effect of Interleukin (IL)-12 in the Absence of Endogenous IFN-{gamma}

A Role for Intrinsic Tumor Immunogenicity and IL-151

Giorgia Gri, Claudia Chiodoni, Elena Gallo, Antonella Stoppacciaro, Foo Y. Liew and Mario P. Colombo2

Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy [G. G., C. C., E. G., M. P. C.]; Department of Experimental Medicine and Pathology, 2nd Chair of Pathology, University of Rome "La Sapienza," 00161 Rome, Italy [A. S.]; and Department of Immunology and Bacteriology, University of Glasgow, Glasgow G11 6NT, United Kingdom [F. Y. L.]

IFN-{gamma} knockout mice (GKO) rejected C26 colon carcinoma cells transduced to secrete interleukin(IL)-12 but do not reject similarly transduced TSA mammary adenocarcinoma (C26/12 and TSA/12 cells, respectively). To determine whether such difference could be because of a different tumor response to IFN-{gamma}, we injected BALB/c mice with TSA, C26, and their IL-12-transduced counterparts rendered unresponsive to IFN-{gamma} by stable transduction of a dominant negative (DN), truncated IFN-{gamma} receptor {alpha} chain. TSA/DN and C26/DN showed the same in vivo growth kinetics as parental cells, whereas coexpression of IL-12 induced rejection independent of tumor-cell responsiveness to IFN-{gamma}. This suggests that the role of IFN-{gamma} is primarily in activating the host immune response, which appears to depend on the intrinsic immunogenicity of the target tumor. C26 and TSA share a common tumor-associated antigen, yet C26 cells are more immunogenic than TSA. C26/12 expressed 10-fold higher levels of class I MHC molecules and induced higher CTL activity compared with TSA/12 cells in GKO mice. Moreover, whereas in GKO mice the TSA/12 tumor was associated with a greater number of infiltrating T cells, only those infiltrating C26/12 tumor expressed the activation marker OX40. The search for cytokine(s) that might contribute in determining the different T-cell response to these IL-12-transduced tumors in GKO mice revealed a role of IL-15. In situ hybridization showed IL-15 expression in C26/12 but not in TSA/12 tumors. In addition, injection of GKO mice with soluble IL-15 receptor-{alpha} to block IL-15 expression prevented rejection of C26/12 cells. Together, the results suggest that in the absence of IFN-{gamma}, IL-12 can exert antitumor activity through alternative mechanisms, depending on the tumor cell type and the availability of cytokines that can replace IFN-{gamma} in sustaining T-cell functions.




This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Numasaki, M. Tagawa, F. Iwata, T. Suzuki, A. Nakamura, M. Okada, Y. Iwakura, S. Aiba, and M. Yamaya
IL-28 Elicits Antitumor Responses against Murine Fibrosarcoma
J. Immunol., April 15, 2007; 178(8): 5086 - 5098.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Mortara, P. Castellani, R. Meazza, G. Tosi, A. De Lerma Barbaro, F. A. Procopio, A. Comes, L. Zardi, S. Ferrini, and R. S. Accolla
CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory.
Clin. Cancer Res., June 1, 2006; 12(11): 3435 - 3443.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Comes, O. Rosso, A. M. Orengo, E. Di Carlo, C. Sorrentino, R. Meazza, T. Piazza, B. Valzasina, P. Nanni, M. P. Colombo, et al.
CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine
J. Immunol., February 1, 2006; 176(3): 1750 - 1758.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Q. Lin, R. Lai, L. R. Chirieac, C. Li, V. A. Thomazy, I. Grammatikakis, G. Z. Rassidakis, W. Zhang, Y. Fujio, K. Kunisada, et al.
Constitutive Activation of JAK3/STAT3 in Colon Carcinoma Tumors and Cell Lines: Inhibition of JAK3/STAT3 Signaling Induces Apoptosis and Cell Cycle Arrest of Colon Carcinoma Cells
Am. J. Pathol., October 1, 2005; 167(4): 969 - 980.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Croce, R. Meazza, A. M. Orengo, L. Radic', B. De Giovanni, C. Gambini, B. Carlini, V. Pistoia, L. Mortara, R. S. Accolla, et al.
Sequential Immunogene Therapy with Interleukin-12- and Interleukin-15-Engineered Neuroblastoma Cells Cures Metastatic Disease in Syngeneic Mice
Clin. Cancer Res., January 15, 2005; 11(2): 735 - 742.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Koka, P. Burkett, M. Chien, S. Chai, D. L. Boone, and A. Ma
Cutting Edge: Murine Dendritic Cells Require IL-15R{alpha} to Prime NK Cells
J. Immunol., September 15, 2004; 173(6): 3594 - 3598.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Guiducci, E. Di Carlo, M. Parenza, M. Hitt, M. Giovarelli, P. Musiani, and M. P. Colombo
Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor
J. Immunol., April 1, 2004; 172(7): 4026 - 4036.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Shi, S. Cao, M. Mitsuhashi, Z. Xiang, and X. Ma
Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma via IFN-{gamma}-Independent Mechanisms
J. Immunol., April 1, 2004; 172(7): 4111 - 4122.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Di Carlo, A. Comes, A. M. Orengo, O. Rosso, R. Meazza, P. Musiani, M. P. Colombo, and S. Ferrini
IL-21 Induces Tumor Rejection by Specific CTL and IFN-{gamma}-Dependent CXC Chemokines in Syngeneic Mice
J. Immunol., February 1, 2004; 172(3): 1540 - 1547.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Kuniyasu, H. Ohmori, T. Sasaki, T. Sasahira, K. Yoshida, Y. Kitadai, and I. J. Fidler
Production of Interleukin 15 by Human Colon Cancer Cells Is Associated with Induction of Mucosal Hyperplasia, Angiogenesis, and Metastasis
Clin. Cancer Res., October 15, 2003; 9(13): 4802 - 4810.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.